• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Innovation in hematology. Perspectives: CML 2016.血液学创新。观点：2016年慢性粒细胞白血病
Haematologica. 2016 Jun;101(6):657-9. doi: 10.3324/haematol.2016.142877.
2
New perspectives with interferon alpha. The German CML study group experience.干扰素α带来的新视角。德国慢性粒细胞白血病研究组的经验。
Bone Marrow Transplant. 1994;14 Suppl 3:S14-20.
3
Modern management of chronic myelogenous leukemia (CML).慢性粒细胞白血病（CML）的现代管理
Cancer Invest. 1988;6(6):737-42. doi: 10.3109/07357908809078041.
4
Interferon in CML.慢性粒细胞白血病中的干扰素
Br J Hosp Med. 1988 Jul;40(1):77.
5
Hematology: the red science.血液学：红色的科学。
Pathology. 1993 Jan;25(1):39-47. doi: 10.3109/00313029309068900.
6
[International Congress of the American Society of Hematology, Philadelphia, 6-10 December 2002].
Rev Med Interne. 2003 Jul;24(7):485-90. doi: 10.1016/s0248-8663(03)00151-6.
7
Chronic myelogenous leukemia: biology and therapy.
Leukemia. 1993 Apr;7(4):653-8.
8
Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.慢性粒细胞白血病（CML）的基因治疗：一种逆转录病毒载体，可使造血祖细胞对甲氨蝶呤产生抗性，并使CML祖细胞在体内功能正常且无致瘤性。
Blood. 1997 Dec 15;90(12):4687-98.
9
[Five breakthroughs for hematology].
Lakartidningen. 2000 Feb 2;97(5):472-3.
10
CML: a model disease with a defined oncogenic driver.慢性粒细胞白血病：一种具有明确致癌驱动因素的模型疾病。
Clin Adv Hematol Oncol. 2011 Mar;9(3):247-8.

引用本文的文献

1
Prognostic scoring systems in chronic myeloid leukaemia.慢性髓性白血病的预后评分系统
Leukemia. 2025 May;39(5):1046-1052. doi: 10.1038/s41375-025-02606-6. Epub 2025 Apr 15.
2
Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients.计算建模揭示了慢性髓性白血病患者实现无治疗缓解的关键驱动因素。
NPJ Syst Biol Appl. 2024 Apr 27;10(1):45. doi: 10.1038/s41540-024-00370-4.
3
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.二代酪氨酸激酶抑制剂作为一线治疗药物引入后慢性髓性白血病治疗方式和结局的变化：CML 合作研究组的一项多机构回顾性研究。
Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8.
4
Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.血液系统疾病中抗肿瘤治疗的心血管毒性：聚焦改善治疗管理的分子机制
J Clin Med. 2024 Mar 9;13(6):1574. doi: 10.3390/jcm13061574.
5
Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing.使用单分子长读长测序技术快速检测髓系肿瘤融合基因
PLOS Glob Public Health. 2023 Sep 12;3(9):e0002267. doi: 10.1371/journal.pgph.0002267. eCollection 2023.
6
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.慢性髓性白血病患者停用伊马替尼、达沙替尼和尼洛替尼后的无治疗缓解
Blood Res. 2023 Apr 30;58(S1):S58-S65. doi: 10.5045/br.2023.2023035. Epub 2023 Apr 7.
7
Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?免疫治疗方案中对脐血来源的自然杀伤细胞的利用：仅仅是一个承诺吗？
Cancers (Basel). 2022 Sep 13;14(18):4439. doi: 10.3390/cancers14184439.
8
Precision Medicine in Therapy of Non-solid Cancer.精准医学在非实体瘤治疗中的应用
Handb Exp Pharmacol. 2023;280:35-64. doi: 10.1007/164_2022_608.
9
A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.酪氨酸激酶抑制剂治疗慢性髓性白血病患者的心脏血液学监测新范式
Cureus. 2022 Jun 8;14(6):e25766. doi: 10.7759/cureus.25766. eCollection 2022 Jun.
10
Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia.伴有骨髓增生异常综合征和慢性粒细胞白血病的局灶性原始细胞危象
Leuk Res Rep. 2020 Oct 6;14:100225. doi: 10.1016/j.lrr.2020.100225. eCollection 2020.

本文引用的文献

1
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.能预测一线伊马替尼治疗慢性期 CML 患者早期分子反应失败的基因表达特征。
Blood Adv. 2019 May 28;3(10):1610-1621. doi: 10.1182/bloodadvances.2019000195.
2
Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.荷兰慢性髓性白血病：一项基于人群的研究，涉及1989年至2012年期间3585例患者的发病率、治疗及生存情况
Eur J Haematol. 2016 Aug;97(2):145-54. doi: 10.1111/ejh.12695. Epub 2015 Nov 30.
3
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.新诊断慢性髓性白血病患者的长期预后：干细胞移植与药物治疗的随机对照比较
Leukemia. 2016 Mar;30(3):562-9. doi: 10.1038/leu.2015.281. Epub 2015 Oct 14.
4
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.考虑到慢性髓性白血病患者的疾病特异性死亡，长期生存的预后。
Leukemia. 2016 Jan;30(1):48-56. doi: 10.1038/leu.2015.261. Epub 2015 Sep 29.
5
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.合并症对慢性髓性白血病患者总生存的影响：随机CML研究IV的结果
Blood. 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27.
6
CML--Where do we stand in 2015?慢性粒细胞白血病——2015年我们处于什么状况？
Ann Hematol. 2015 Apr;94 Suppl 2:S103-5. doi: 10.1007/s00277-015-2331-1. Epub 2015 Mar 27.
7
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.EUTOS 基于人群的注册研究：20 个欧洲国家 2904 例 CML 患者的发病情况和临床特征。
Leukemia. 2015 Jun;29(6):1336-43. doi: 10.1038/leu.2015.73. Epub 2015 Mar 18.
8
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.慢性髓性白血病治疗后深度分子反应评分的实验室建议。
Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5.
9
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.伊马替尼一线治疗下e13a2与e14a2 BCR-ABL1驱动的慢性髓性白血病的不同特征。
Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May 16.
10
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.慢性髓性白血病中BCR-ABL抑制剂治疗依从性的测量：现状与未来挑战
Haematologica. 2014 Mar;99(3):437-47. doi: 10.3324/haematol.2012.082511.

Innovation in hematology. Perspectives: CML 2016.

作者信息

Hehlmann Rüdiger

机构信息

Heidelberg University, Mannheim, Germany

出版信息

Haematologica. 2016 Jun;101(6):657-9. doi: 10.3324/haematol.2016.142877.

DOI:10.3324/haematol.2016.142877
PMID:27252510
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5013944/
Abstract
摘要